Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCALP 2
2023-504421-39-00Phase 3Completed
- Sponsor
- Cassiopea S.p.A.
- Start
- Oct 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in androgenetic alopecia (AGA) comparing Clascoterone BID with Vehicle BID (2 arms). Primary endpoints: Change from Pivotal Part 1 Baseline in non-vellus Target Area Hair Count (TAHC) at Month 6 and Subject’s assessment of own hair coverage at Month 6 (MAA-PRO core measure item 2 responder). Started Oct 2023; status: completed.
02
Drugs
clascoterone
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on 2023-504421-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504421-39-00.